Araceli Naranjo

4.2k total citations · 1 hit paper
14 papers, 1.5k citations indexed

About

Araceli Naranjo is a scholar working on Oncology, Immunology and Genetics. According to data from OpenAlex, Araceli Naranjo has authored 14 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 4 papers in Immunology and 3 papers in Genetics. Recurrent topics in Araceli Naranjo's work include CAR-T cell therapy research (11 papers), Virus-based gene therapy research (3 papers) and Cancer Research and Treatments (2 papers). Araceli Naranjo is often cited by papers focused on CAR-T cell therapy research (11 papers), Virus-based gene therapy research (3 papers) and Cancer Research and Treatments (2 papers). Araceli Naranjo collaborates with scholars based in United States, South Africa and Germany. Araceli Naranjo's co-authors include Michael C. Jensen, Wen-Chung Chang, Christine L. Wright, Julie R. Ostberg, Jamie R. Wagner, Stephen J. Forman, Christine E. Brown, David DiGiusto, Julie R. Park and Marilyn L. Slovak and has published in prestigious journals such as Blood, Clinical Cancer Research and Molecular Therapy.

In The Last Decade

Araceli Naranjo

14 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

2015 592 citations Christine E. Brown, Behnam Badie et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Araceli Naranjo United States	8	1.3k	610	484	420	335	14	1.5k
Meenakshi Hegde United States	13	1.4k 1.0×	538 0.9×	607 1.3×	423 1.0×	414 1.2×	36	1.6k
Donald R. Shaffer United States	12	1.4k 1.0×	730 1.2×	485 1.0×	377 0.9×	417 1.2×	23	1.8k
Jamie R. Wagner United States	11	1.5k 1.1×	625 1.0×	570 1.2×	476 1.1×	410 1.2×	28	1.8k
Mark B. Leick United States	16	1.4k 1.1×	518 0.8×	505 1.0×	408 1.0×	526 1.6×	47	1.8k
Zhongzhen Yi United States	11	1.0k 0.8×	459 0.8×	418 0.9×	294 0.7×	283 0.8×	17	1.2k
Vita S. Brawley United States	10	1.0k 0.8×	429 0.7×	442 0.9×	326 0.8×	313 0.9×	14	1.2k
Tiara T. Byrd United States	10	1.0k 0.8×	430 0.7×	496 1.0×	315 0.8×	271 0.8×	18	1.2k
Kevin Chow United States	11	982 0.7×	416 0.7×	382 0.8×	263 0.6×	270 0.8×	16	1.2k
Ignazio Caruana Italy	18	1.4k 1.1×	709 1.2×	488 1.0×	496 1.2×	556 1.7×	35	1.8k
Darya Alizadeh United States	13	942 0.7×	514 0.8×	393 0.8×	220 0.5×	417 1.2×	25	1.3k

Countries citing papers authored by Araceli Naranjo

Since Specialization

Citations

This map shows the geographic impact of Araceli Naranjo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Araceli Naranjo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Araceli Naranjo more than expected).

Fields of papers citing papers by Araceli Naranjo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Araceli Naranjo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Araceli Naranjo. The network helps show where Araceli Naranjo may publish in the future.

Co-authorship network of co-authors of Araceli Naranjo

This figure shows the co-authorship network connecting the top 25 collaborators of Araceli Naranjo. A scholar is included among the top collaborators of Araceli Naranjo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Araceli Naranjo. Araceli Naranjo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Barish, Michael E., Lihong Weng, Massimo D’Apuzzo, et al.. (2020). P855 High-resolution maps of heterogeneous antigen expression in glioblastoma and implications for immunotherapy. Poster presentations. A6.1–A6. 1 indexed citations

Khaled, Samer K., Suzette Blanchard, Xiuli Wang, et al.. (2018). Adult Patients with ALL Treated with CD62L+ T Naïve/Memory-Enriched T Cells Expressing a CD19-CAR Mediate Potent Antitumor Activity with a Low Toxicity Profile. Blood. 132(Supplement 1). 4016–4016. 7 indexed citations

Popplewell, Leslie, Xiuli Wang, Suzette Blanchard, et al.. (2018). CD19-CAR Therapy Using Naive/Memory or Central Memory T Cells Integrated into the Autologous Stem Cell Transplant Regimen for Patients with B-NHL. Blood. 132(Supplement 1). 610–610. 6 indexed citations

Brown, Christine E., Darya Alizadeh, Renate Starr, et al.. (2016). ATIM-13. PHASE I STUDY OF CHIMERIC ANTIGEN RECEPTOR-ENGINEERED T CELLS TARGETING IL13Rα2 FOR THE TREATMENT OF GLIOBLASTOMA. Neuro-Oncology. 18(suppl_6). vi20–vi20. 3 indexed citations

Brown, Christine E., Behnam Badie, Michael E. Barish, et al.. (2015). Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma. Clinical Cancer Research. 21(18). 4062–4072. 592 indexed citations breakdown →

Popplewell, Leslie, Xiuli Wang, Araceli Naranjo, et al.. (2015). Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma. Blood. 126(23). 930–930. 3 indexed citations

Brown, Christine E., Renate Starr, Araceli Naranjo, et al.. (2013). Adoptive transfer of IL13Rα2-specific T cells for the treatment of glioblastoma: building on clinical achievements with second-generation CARs. Journal for ImmunoTherapy of Cancer. 1(S1). 1 indexed citations

Wang, Xiuli, Araceli Naranjo, Christine E. Brown, et al.. (2012). Phenotypic and Functional Attributes of Lentivirus-modified CD19-specific Human CD8+ Central Memory T Cells Manufactured at Clinical Scale. Journal of Immunotherapy. 35(9). 689–701. 111 indexed citations

Park, Julie R., David DiGiusto, Marilyn L. Slovak, et al.. (2007). Adoptive Transfer of Chimeric Antigen Receptor Re-directed Cytolytic T Lymphocyte Clones in Patients with Neuroblastoma. Molecular Therapy. 15(4). 825–833. 474 indexed citations

10.

Brown, Christine E., Christine L. Wright, Araceli Naranjo, et al.. (2005). Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing. Journal of Immunological Methods. 297(1-2). 39–52. 59 indexed citations

11.

Brown, Christine E., Jamie R. Wagner, Araceli Naranjo, et al.. (2005). A quantitative high-throughput chemotaxis assay using bioluminescent reporter cells. Journal of Immunological Methods. 302(1-2). 78–89. 10 indexed citations

12.

González, Sergio, Araceli Naranjo, Lisa Marie Serrano, et al.. (2004). Genetic engineering of cytolytic T lymphocytes for adoptive T‐cell therapy of neuroblastoma. The Journal of Gene Medicine. 6(6). 704–711. 49 indexed citations

13.

Cooper, Laurence J.N., Max S. Topp, Lisa Marie Serrano, et al.. (2003). T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B–lineage leukemia effect. Blood. 101(4). 1637–1644. 200 indexed citations

14.

Naranjo, Araceli, et al.. (1986). [Effect of protein-calorie malnutrition on mandibular growth in rats].. PubMed. 22(2). 168–76. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact